Lakomy DS, Wu J, Lombe D, et al. - Literature on hematologic and immune markers among patients with cervical cancer treated with chemoradiation was reviewed and their association with recurrence and survival was determined. Following PRISMA guidelines, researchers carried out this systematic review via searches of Ovid MEDLINE, Ovid Embase, and the Cochrane Library. Of 737 identified studies, 314 assessed immune biomarkers in immunocompetent patients (30 included in the final analysis) and 327 studies in immunosuppressed patients (5 included in the final analysis). Findings suggest a complex immunologic interplay at work in cervical cancer development, progression, and treatment. Robust evidence was gained indicating lymphopenia and elevated neutrophil-to-lymphocyte ratio as prognostic for worse outcomes with other markers displaying potential associations as well.